Every Form 4 that Travere Therapeutics, Inc. (TVTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVTX filings page.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed reported planned stock sales under a Rule 10b5-1 trading plan. On February 4, 2026, she sold 2,485 shares of common stock at a weighted average price of $32.07 and 509 shares at a weighted average price of $32.74.
The filing notes that the plan was adopted on June 16, 2025 and that the transactions include shares sold to cover tax obligations from vesting restricted stock units. After these sales, Reed directly owned 105,211 shares of Travere Therapeutics common stock.
Travere Therapeutics CEO Eric M. Dube reported multiple equity transactions. On January 31, 2026, he acquired 113,800 shares of common stock at $0 through restricted stock units and received an option for 303,600 shares at an exercise price of $33.095 per share.
On February 3, 2026, he sold 66,452 shares at $32.06 and 33,635 shares at $32.70 under a pre-arranged Rule 10b5-1 trading plan, which also covered tax obligations from vesting. After these transactions, he directly held 432,886 common shares and 303,600 stock options.
Travere Therapeutics’ chief medical officer, Jula Inrig, reported equity grants and a tax-related share sale. On 01/31/2026, she acquired 28,130 shares of common stock at $0 through restricted stock unit settlement, bringing her holdings to 114,441 shares before a later sale.
That same day she received an employee stock option for 75,000 shares of common stock at an exercise price of $33.095, expiring on 01/31/2036, with vesting over four years. On 02/03/2026, she sold 6,956 shares of common stock at $32.12 per share to cover tax withholding from the vested units, a mandated “sell to cover” transaction, not a discretionary trade. After the sale, she directly owned 107,485 common shares and 75,000 stock options.
Travere Therapeutics' Chief Financial Officer Christopher R. Cline reported equity compensation activity and a related share sale. On January 31, 2026, he acquired 28,130 shares of common stock for $0 upon settlement of restricted stock units and held 120,213 shares afterward.
That same day he received an employee stock option for 75,000 shares at an exercise price of $33.095, expiring on January 31, 2036, with one-fourth vesting after one year and the rest vesting in 36 monthly installments. On February 3, 2026, he sold 7,242 shares at $32.12 per share to cover tax withholding from the vested restricted stock units, leaving him with 112,971 directly owned shares; the filing notes this was a mandated “sell to cover” transaction, not a discretionary trade.
Travere Therapeutics, Inc. Chief Commercial Officer Peter Heerma reported equity transactions in company stock. On January 31, 2026, he acquired 26,120 shares of common stock at $0 per share in connection with restricted stock units, bringing his direct holdings to 139,133 shares.
That same day, he received an employee stock option grant for 69,640 shares at an exercise price of $33.095 per share, vesting over four years. On February 3, 2026, he sold 7,310 shares at $32.12 per share to cover tax withholding owed on vested restricted stock units. The sale was executed under a mandatory "sell to cover" arrangement and is not described as a discretionary trade. After this sale, he directly held 131,823 shares of Travere common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported routine equity compensation and a planned share sale. On 01/31/2026 he acquired 20,090 shares of common stock for $0 through restricted stock units and received an employee stock option for 53,570 shares at an exercise price of $33.095 per share.
These options vest over time, with one-fourth vesting on the first anniversary of grant and the remainder in 36 monthly installments. On 02/03/2026 he sold 12,446 shares of common stock at $32.87 per share under a Rule 10b5-1 trading plan, and held 109,087 common shares and 53,570 options directly afterward.
Travere Therapeutics SVP and Chief Accounting Officer Calvin Sandra reported equity awards and a tax-related stock sale. On January 31, 2026, she received 15,180 shares of common stock through vested restricted stock units and an employee stock option for 20,160 shares at an exercise price of $33.095 per share.
On February 3, 2026, she sold 4,333 shares of common stock at $32.12 per share to cover tax withholding from the RSU settlement, a mandated "sell to cover" transaction rather than a discretionary trade. After these transactions, she directly owned 49,080 shares of common stock and 20,160 stock options.
Travere Therapeutics' chief legal officer, Elizabeth E. Reed, reported routine equity compensation and a related tax sale. On 01/31/2026 she received 25,110 shares of common stock for $0 as restricted stock units settled, bringing her direct holdings to 115,380 shares. On 02/03/2026, 7,175 shares were sold at $32.12 solely to cover tax withholding on the vesting; the company’s plan requires this mandated “sell to cover” transaction, so it was not a discretionary trade. She also received an employee stock option on 01/31/2026 for 66,960 shares at an exercise price of $33.095, vesting 25% after one year and the remainder in 36 monthly installments, giving her 66,960 options directly held.
Travere Therapeutics CEO Eric M. Dube reported planned option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on June 16, 2025. On January 23 and January 27, 2026, he exercised employee stock options for a total of 60,000 shares of common stock at an exercise price of $15.46 per share and sold the same number of shares at weighted average prices of $30.0127 and $30.097, respectively. Following these transactions, he held 419,173 shares of Travere common stock directly, and continued to hold fully vested employee stock options with a $15.46 exercise price expiring on January 31, 2030, including positions of 171,865 and 120,000 options.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed reported an option exercise and share sale in Travere Therapeutics, Inc. common stock. On January 20, 2026, she exercised 10,000 employee stock options at an exercise price of $19.08 per share and received 10,000 shares of common stock.
That same day, she sold 10,000 shares of Travere common stock at a weighted average price of $27.3420 per share under a Rule 10b5-1(c) trading plan adopted on June 16, 2025, tied to a stock option grant from January 4, 2017 that expires on January 4, 2027. After these transactions, she directly beneficially owned 90,270 shares of common stock, which include 392 shares acquired through the 2017 Employee Stock Purchase Plan, and held 30,000 employee stock options that are fully vested and exercisable.
Travere Therapeutics’ Chief Medical Officer sells shares tied to equity awards and a trading plan. Reporting person Jula Inrig, Chief Medical Officer of Travere Therapeutics, Inc., reported two sales of common stock. On January 5, 2026, 2,031 shares were sold at $40.18 per share, and on January 6, 2026, 445 shares were sold at $37.75 per share. After these transactions, the reporting person held 86,311 shares of common stock directly.
According to the footnotes, the January 5 sale reflects shares sold to cover tax withholding owed when restricted stock units vested, under the company’s equity incentive plan and a mandated “sell to cover” arrangement, and is described as not a discretionary trade. The January 6 sale was made under a written plan adopted on May 28, 2025 that is intended to comply with Rule 10b5-1(c), and it also includes shares sold to cover tax obligations from vesting restricted stock units.
Travere Therapeutics, Inc. reported an insider stock sale by its SVP and Chief Accounting Officer. On 12/15/2025, the executive sold 2,910 shares of Travere common stock at $36 per share, according to a Form 4 insider trading report.
After this transaction, the officer beneficially owns 45,635 shares directly. The filing notes that the sale was made under a written trading plan adopted on June 10, 2025 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.
Travere Therapeutics, Inc. reported an insider stock transaction by its Chief Financial Officer on 12/01/2025. The CFO exercised an employee stock option to acquire 20,000 shares of common stock at an exercise price of $16.23 per share, then sold 20,000 shares of common stock the same day. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025 and related to an option grant originally made on May 19, 2016.
The weighted average sale price was $35.0101 per share, with individual sale prices ranging from $34.64 to $35.41. Following these transactions, the CFO directly beneficially owned 92,083 shares of Travere Therapeutics common stock.
Travere Therapeutics (TVTX) reported insider activity by its SVP & Chief Accounting Officer on 11/04/2025. The officer exercised multiple employee stock options and sold shares pursuant to a Rule 10b5-1(c) plan adopted on June 10, 2025.
Exercises: 10,000 shares at $25.25; 17,500 at $26.88; 15,000 at $27.50; 12,500 at $22.40; and 6,250 at $8.93. Sale: 67,115 shares at $36. Following these transactions, beneficial ownership stood at 48,545 shares directly.
Travere Therapeutics (TVTX) reported an insider transaction by a director on 10/31/2025. The director exercised options for 8,000 shares at $16.33 and 10,000 shares at $17.44, then sold 18,000 shares at a weighted average price of $35.0334 (range $35.00–$35.15) under a Rule 10b5-1(c) trading plan adopted on June 16, 2025.
Following these transactions, the director beneficially owned 55,500 shares directly. The reported stock options were fully vested and exercisable.
Travere Therapeutics (TVTX) reported an insider transaction by its Chief Commercial Officer. On 10/31/2025, the officer sold 5,591 shares of common stock at $35 per share under a Rule 10b5-1 trading plan adopted on June 16, 2025. On 11/03/2025, the officer made a charitable gift of 1,078 shares to a donor advised fund, also pursuant to the same 10b5-1 plan.
Following these transactions, the officer beneficially owned 117,993 shares, held directly.
Travere Therapeutics (TVTX) reported insider transactions by its Chief Executive Officer and director under a Rule 10b5-1(c) trading plan adopted on June 16, 2025. On 10/28/2025, the officer exercised 92,872 options at $15.46 and sold 92,872 shares at a weighted average price of $30.379 (range $30.00–$30.97). On 10/29/2025, the officer exercised 27,128 options at $15.46 and sold 27,128 shares at a weighted average price of $30.1192 (range $30.00–$30.48).
Following the reported transactions, the officer beneficially owned 419,173 shares of common stock directly. Derivative securities beneficially owned following the transactions totaled 180,000 options with a $15.46 exercise price expiring on 01/31/2030. The option referenced is fully vested and exercisable.
Travere Therapeutics (TVTX) reported an insider transaction by its Chief Commercial Officer. On 10/28/2025, the officer sold 2,662 shares of common stock at $30 per share (transaction code S), leaving 124,662 shares beneficially owned directly after the sale.
The filing notes the sale was made under a Rule 10b5-1(c) trading plan adopted on June 16, 2025.